Clinical Trials List
Protocol NumberKF-CSR02-001
NCT Number(ClinicalTrials.gov Identfier)NCT04601428
Active
2020-06-01 - 2026-12-31
Others
Recruiting4
CSR02-Fab-TF as Hepatic Intra-arterial Therapy in Intermediate Stage B or Limited Advanced Stage C Hepatocellular Carcinoma (HCC): Dose-Escalation Study to Assess Safety and Tolerability
-
Trial Applicant
A2 HEALTHCARE TAIWAN CORPORATION
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/02/01
Investigators and Locations
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Sheng-chieh Chou Division of General Internal Medicine
- Chiun Hsu Division of Hematology & Oncology
- 蘇東弘 Division of General Internal Medicine
- 何承懋 Division of General Surgery
- Chih-Hung Hsu Division of Hematology & Oncology
- 曾岱宗 醫學研究部
- Chia-Chi Lin Division of Hematology & Oncology
- Chien-Hung Chen Division of General Internal Medicine
- Ming-Chih Ho Division of General Surgery
- 楊宏志 Division of General Internal Medicine
The Actual Total Number of Participants Enrolled
0 Recruiting
Principal Investigator
Chia-Jui Yen
Co-Principal Investigator
- Hsin-Yu Kuo Digestive System Department
- 簡世杰 Digestive System Department
- Yih-Jyh Lin Division of Gastroenterological Surgery
- 劉奕廷 Division of Hematology & Oncology
- Chien-Jui Huang Digestive System Department
- Chiu Hung Chiu Digestive System Department
- Liu Yi-Sheng Division of Radiology
The Actual Total Number of Participants Enrolled
0 Recruiting
Condition/Disease
Hepatocellular Carcinoma (HCC)
Objectives
The purpose of this trial is to test the safety of the investigational drug CSR02-Fab-TF and determine the optimal dosage for future clinical trials of this drug in the treatment of liver cancer. This drug has been tested in animals, but only in humans until this trial. This trial will test different dosages of the drug to determine the highest tolerated dose and to provide a preliminary assessment of its efficacy in treating liver cancer.
Test Drug
注射液
Active Ingredient
CSR02-Fab-TF
Dosage Form
279
Dosage
1mg/ml
Endpoints
Primary Objectives:
1. To determine the safety and tolerability of CSR02-Fab-TF
2. To determine the maximum tolerated dose (MTD) or the clinically active dose of CSR02-Fab-TF
1. To determine the safety and tolerability of CSR02-Fab-TF
2. To determine the maximum tolerated dose (MTD) or the clinically active dose of CSR02-Fab-TF
Inclution Criteria
Inclusion Criteria:
Age ≥ 18 years
Diagnosis of HCC by at least one of the following criteria:
Histological confirmation;
Magnetic resonance imaging (MRI) or computerized tomography (CT) consistent with liver cirrhosis AND at least one solid liver lesion > 1 cm with intense contrast uptake during the arterial phase followed by contrast washout during the venous phase regardless of alpha-fetal protein (AFP) level
Barcelona Clinic Liver Cancer (BCLC) Intermediate Stage B or limited Advanced Stage C (see Protocol Section 3.1). Patients with Stage C disease should have received or been offered and chosen not to receive systemic therapy
Inadequate response to prior liver-directed therapy (e.g., TACE, bland embolization, Y90, ablation, radiation therapy) to the same targeted area or progressive disease after prior liver-directed therapy) or to one or more systemic therapies
Not a candidate for curative resection, liver transplantation, or percutaneous ablation (See Protocol Appendix 3)
Eastern Collective Oncology Group (ECOG) performance status ≤1 (See Protocol Appendix 5)
Adequate laboratory parameters, including:
Serum total bilirubin ≤ 2x ULN
Alkaline phosphatase, aspartate aminotransferase (AST) and aspartate aminotransferase (ALT) < 5 x ULN;
Serum creatinine ≤ 1.5 mg/dL;
Prothrombin time (international normalized ratio; INR) ≤ 1.5;
Absolute neutrophil count > 1000/μL;
Platelet count > 75,000/μL;
Hgb > 8 g/dL
Acceptable pulmonary status, including room air O2 saturation > 90%
Child-Pugh A-B7 without clinically significant ascites (See Protocol Appendix 4)
Signed informed consent
All subjects must be surgically sterile, at least two years post-menopausal (if female), or agree to use adequate, effective contraception approved by the Investigator until two (2) months after receiving a final dose of CSR02-Fab-TF
Age ≥ 18 years
Diagnosis of HCC by at least one of the following criteria:
Histological confirmation;
Magnetic resonance imaging (MRI) or computerized tomography (CT) consistent with liver cirrhosis AND at least one solid liver lesion > 1 cm with intense contrast uptake during the arterial phase followed by contrast washout during the venous phase regardless of alpha-fetal protein (AFP) level
Barcelona Clinic Liver Cancer (BCLC) Intermediate Stage B or limited Advanced Stage C (see Protocol Section 3.1). Patients with Stage C disease should have received or been offered and chosen not to receive systemic therapy
Inadequate response to prior liver-directed therapy (e.g., TACE, bland embolization, Y90, ablation, radiation therapy) to the same targeted area or progressive disease after prior liver-directed therapy) or to one or more systemic therapies
Not a candidate for curative resection, liver transplantation, or percutaneous ablation (See Protocol Appendix 3)
Eastern Collective Oncology Group (ECOG) performance status ≤1 (See Protocol Appendix 5)
Adequate laboratory parameters, including:
Serum total bilirubin ≤ 2x ULN
Alkaline phosphatase, aspartate aminotransferase (AST) and aspartate aminotransferase (ALT) < 5 x ULN;
Serum creatinine ≤ 1.5 mg/dL;
Prothrombin time (international normalized ratio; INR) ≤ 1.5;
Absolute neutrophil count > 1000/μL;
Platelet count > 75,000/μL;
Hgb > 8 g/dL
Acceptable pulmonary status, including room air O2 saturation > 90%
Child-Pugh A-B7 without clinically significant ascites (See Protocol Appendix 4)
Signed informed consent
All subjects must be surgically sterile, at least two years post-menopausal (if female), or agree to use adequate, effective contraception approved by the Investigator until two (2) months after receiving a final dose of CSR02-Fab-TF
Exclusion Criteria
Exclusion Criteria:
Eligible for transplantation by Milan criteria (Protocol Appendix 3) or potentially eligible if successfully "down staged" by pre-transplant therapy
Prior organ transplantation
Any small molecule drug treatment for HCC (including TACE) within the previous 30 days, treatment with biological agents or any investigational therapy within the previous 60 days, or treatment with Y90 within the previous 90 days.
Previously treated malignancies from which the subject has not been disease-free for at least 2 years, except for adequately treated non-melanoma skin cancer, in situ cancer, or low-grade prostate or bladder cancer
Severe chronic obstructive or other pulmonary disease with hypoxemia that requires supplementary oxygen or clinically significant pleural effusions
New York Heart Association (NYHA) Class III or IV, cardiac disease, myocardial infarction within 3 months prior to therapy, unstable arrhythmia, symptomatic peripheral arterial vascular disease, or presence of an artificial or other vascular device requiring chronic anticoagulation (See Protocol Appendix 6)
Any of the following risks related to QT/QTc interval:
Baseline prolongation of QT/QTc interval (repeated interval > 480 milliseconds using Frederica's QT correction formula);
History of additional risk factors for Torsades de Pointes (e.g. heart failure, hypokalemia, family history of Long QT syndrome);
Concomitant medications that have a known risk for prolongation of the QT/QTc interval (see https://crediblemeds.org/new-drug-list/)
Major surgery, vascular injury, or serious illness within the previous 60 days
Known inherited thrombophilia (hypercoagulable state) or history of unprovoked venous or arterial thrombosis
Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy at screening. Subjects with prior HBV (positive HBSAg) must have HBV viral load < 2000 IU/mL or be receiving concurrent anti-HBV therapy to be eligible. Subjects on anti-HBV therapy must have been on treatment with a viral load maintained at < 2000 IU/mL for at least 4 weeks prior to first dose and continue on this same therapy throughout study treatment. Subjects with HCV infection are eligible if other eligibility criteria are met
Females who are breast-feeding
Allergy to iodinated contrast medium that is uncontrolled or refractory to medical therapy
Therapeutic anticoagulation that cannot be stopped 24-72 hours before treatment (per Section 4.5) and reinstituted no sooner than 72 hours after therapy
Any concomitant disease or condition that could interfere with the conduct of the study, or that would, in the opinion of the Investigator, pose an unacceptable risk to the subject in this study
Unwillingness or inability to comply with the study protocol for any reason
Eligible for transplantation by Milan criteria (Protocol Appendix 3) or potentially eligible if successfully "down staged" by pre-transplant therapy
Prior organ transplantation
Any small molecule drug treatment for HCC (including TACE) within the previous 30 days, treatment with biological agents or any investigational therapy within the previous 60 days, or treatment with Y90 within the previous 90 days.
Previously treated malignancies from which the subject has not been disease-free for at least 2 years, except for adequately treated non-melanoma skin cancer, in situ cancer, or low-grade prostate or bladder cancer
Severe chronic obstructive or other pulmonary disease with hypoxemia that requires supplementary oxygen or clinically significant pleural effusions
New York Heart Association (NYHA) Class III or IV, cardiac disease, myocardial infarction within 3 months prior to therapy, unstable arrhythmia, symptomatic peripheral arterial vascular disease, or presence of an artificial or other vascular device requiring chronic anticoagulation (See Protocol Appendix 6)
Any of the following risks related to QT/QTc interval:
Baseline prolongation of QT/QTc interval (repeated interval > 480 milliseconds using Frederica's QT correction formula);
History of additional risk factors for Torsades de Pointes (e.g. heart failure, hypokalemia, family history of Long QT syndrome);
Concomitant medications that have a known risk for prolongation of the QT/QTc interval (see https://crediblemeds.org/new-drug-list/)
Major surgery, vascular injury, or serious illness within the previous 60 days
Known inherited thrombophilia (hypercoagulable state) or history of unprovoked venous or arterial thrombosis
Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy at screening. Subjects with prior HBV (positive HBSAg) must have HBV viral load < 2000 IU/mL or be receiving concurrent anti-HBV therapy to be eligible. Subjects on anti-HBV therapy must have been on treatment with a viral load maintained at < 2000 IU/mL for at least 4 weeks prior to first dose and continue on this same therapy throughout study treatment. Subjects with HCV infection are eligible if other eligibility criteria are met
Females who are breast-feeding
Allergy to iodinated contrast medium that is uncontrolled or refractory to medical therapy
Therapeutic anticoagulation that cannot be stopped 24-72 hours before treatment (per Section 4.5) and reinstituted no sooner than 72 hours after therapy
Any concomitant disease or condition that could interfere with the conduct of the study, or that would, in the opinion of the Investigator, pose an unacceptable risk to the subject in this study
Unwillingness or inability to comply with the study protocol for any reason
The Estimated Number of Participants
-
Taiwan
30 participants
-
Global
43 participants
